Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Apr 7;26(16):1990-8.
doi: 10.1016/j.vaccine.2008.02.024. Epub 2008 Feb 26.

Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine

Affiliations
Comparative Study

Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine

Mary Dawn T Co et al. Vaccine. .

Abstract

Thirty adults were tested for humoral and cellular immune responses following immunization with the trivalent inactivated influenza vaccine. Modest but significant inverse correlations between the baseline and the fold changes in the number of IFNgamma-producing cells and the levels of neutralizing antibodies were observed. Specific increases in proliferative responses in the CD8 CD45RA+ population were noted after vaccination. Minimal correlations between neutralizing antibody titers and the number of IFNgamma-producing cells in terms of prevaccination levels or fold increases were observed. These results show specific increases in a CD8 T cell subset and discordant T and B responses induced by the trivalent inactivated influenza vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between the number of IFNγ producing cells at baseline and peak fold increase after immunization using ELISPOT assay. Linear regression analysis was performed using all data available for the three time points for the H3N2 A/Wisconsin/67/05 strain (left panel) and the H1N1 A/New Caledonia virus/20/99 (right panel). SFU= spot forming units
Figure 2
Figure 2
Increase in CD8 CD45RA+ cells capable of virus specific proliferation after influenza vaccination. Typical flow cytometry plot using carboxyfluorescein succinimidyl ester (CFSE) based assay for an individual donor at prevaccination and at Day 64 post vaccination. Media and Phytohemagluttinin controls are shown. CFSE labeled PBMC were stimulated with A/New Caledonia virus/20/99 for 6 days and then surface stained for CD3,CD8 and CD45RA.Cells were analyzed on Flow Jo software by gating on live lymph cells, then CD3 vs side scatter, then CD8 vs. side scatter and then CD45RA vs CFSE. Bolded numbers in the quadrants refers to the percentage of CD8/CFSE+/CD45RA+ or CD8/CFSE+/CD45RA− cells.
Figure 3
Figure 3
Relationships between frequencies of IFNγ producing cells and the neutralizing antibody titers. All analyses were performed using linear regression analysis. A- Correlations between the prevaccination numbers of IFNγ producing cells and prevaccination neutralizing antibody titers for H3N2 A/Wisconsin/67/05 prevaccination ( left, r2 = 0.003 p= 0.74 )and H1N1 A/New Caledonia virus/20/99 (right, r2 = 0.25 p=0.0049). SFU = spot forming units. B- Correlations between the peak post-vaccination fold increases in the number of IFNγ producing cells and peak post-vaccination fold increases in neutralizing antibody titers for H3N2 A/Wisconsin/67/05 (left, r2 = 0.102 p= 0.083) and H1N1 A/New Caledonia virus/20/99 ( right, r2 = 0.001 p= 0.85). SFU = spot forming units. C– Correlations between prevaccination neutralizing antibody titers and peak fold increase in IFNγ producing cells for H3N2 A/Wisconsin/67/05 (left, r2 = 0.005 p= 0.70) and H1N1 A/New Caledonia virus/20/99 (right, r2 = 0.00005 p= 0.97). SFU = spot forming units. D- Correlations between prevaccination IFNγ producing cells and peak fold increase in neutralizing antibody titers for H3N2 A/Wisconsin/67/05 (left, r2 = 0.058 p= 0.196)and H1N1 A/New Caledonia virus/20/99 (right, r2 = 0 .132 p= 0.048). SFU = spot forming units

References

    1. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2004 May 28;53(RR6):1–40. - PubMed
    1. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine. 2002 Aug 19;20(25–26):3068–3087. - PubMed
    1. Belshe RB, Gruber WC. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1947–1951. - PMC - PubMed
    1. Yamada A, Young JF, Ennis FA. Influenza virus subtype-specific cytotoxic T lymphocytes lyse target cells coated with a protein produced in E. coli. The Journal of experimental medicine. 1985 Nov 1;162(5):1720–1725. - PMC - PubMed
    1. Yamada YK, Meager A, Yamada A, Ennis FA. Human interferon alpha and gamma production by lymphocytes during the generation of influenza virus-specific cytotoxic T lymphocytes. J Gen Virol. 1986 Nov;67(Pt 11):2325–2334. - PubMed

Publication types

MeSH terms